June 30, 2022
Brii Biosciences Announces Upcoming Conference Participation in July
June 09, 2022
Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China
